| Species |
Human |
| Protein Construction |
LILRB4/CD85k/ILT3 Domain 1+hinge (Gln22-Lys123)_x000D_
Accession # AAH26309.1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
14.77 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 15-20 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
LILRB4,also known as CD85k and LIR-5, ILT3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. |
| Synonyms |
HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
